NasdaqCM:SLSBiotechs
SELLAS Life Sciences Group (SLS) Nears REGAL Readout As Valuation Questions Return
SELLAS Life Sciences Group (SLS) is back in focus as investors watch for the final analysis of its Phase 3 REGAL trial in acute myeloid leukemia, with the pivotal readout reportedly close.
See our latest analysis for SELLAS Life Sciences Group.
At a share price of $10.29, SELLAS Life Sciences Group has seen a very large 1 year total shareholder return. The 90 day share price return of 108.72% contrasts with a 30 day share price decline of 30.28%, suggesting momentum has cooled as investors...